Compare Adobe Systems Inc (ADBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Merck & Co., Inc. — how do they compare? Adobe Systems Inc trades at $261.4 (market cap $108.50B), while Merck & Co., Inc. trades at $130.11 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 3× Adobe Systems Inc's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | MRK | |
|---|---|---|
Market Cap | $108.50B | $323.00B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $131.84 |
52-Week Low | $193.41 | $77.60 |
Enterprise Value | $109.94B | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.
ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
